Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14–skipping mutation: A series of 6 cases

•46.2 % (6/13) patients with METex14 mutations response to immunotherapy.•Disease control lasted more than 18 months with partial or complete response.•No predictive factor of response to immunotherapy was identified.•Tolerance profile is that of patients without oncogenic mutations. About 2–3% of n...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2020-12, Vol.150, p.21-25
Hauptverfasser:	Mayenga, Marie, Assié, Jean-Baptiste, Monnet, Isabelle, Massiani, Marie-Ange, Tabeze, Laure, Friard, Sylvie, Fraboulet, Séverine, Métivier, Anne-Cécile, Chouaïd, Christos, Zemoura, Leïla, Longchampt, Elisabeth, Callens, Céline, Melaabi, Samia, Couderc, Louis-Jean, Doubre, Hélène
Format:	Artikel
Sprache:	eng
Schlagworte:	Immune checkpoint Immunotherapy MET exon-14–skipping mutation Non-small–cell lung cancer PD-L1
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!